165 related articles for article (PubMed ID: 26885233)
1. Replacement of conventional doxorubicin by pegylated liposomal doxorubicin in standard RCHOP chemotherapy for elderly diffuse large B-Cell lymphoma: a retrospective study in China.
Zhou D; Li L; Bao C; Zhu J; Zhu L; Yang X; Zheng Y; Zhou M; Luo X; Xie W; Ye X
Int J Clin Exp Med; 2015; 8(12):22497-502. PubMed ID: 26885233
[TBL] [Abstract][Full Text] [Related]
2. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.
Oki Y; Ewer MS; Lenihan DJ; Fisch MJ; Hagemeister FB; Fanale M; Romaguera J; Pro B; Fowler N; Younes A; Astrow AB; Huang X; Kwak LW; Samaniego F; McLaughlin P; Neelapu SS; Wang M; Fayad LE; Durand JB; Rodriguez MA
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):152-8. PubMed ID: 25445468
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and cardiac toxicity of different-dose pegylated liposomal doxorubicin in elderly patients with diffuse large B lymphoma.
Li L; Chen R; Zhou D; Sun J; Wang L; Zhu L; Shen H; Xie W; Ye X
Cancer Med; 2023 Feb; 12(4):4184-4194. PubMed ID: 36200320
[TBL] [Abstract][Full Text] [Related]
4. [Non-pegylated liposomal doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab for the treatment of non-Hodgkin's lymphoma: study of 26 patients].
Moreno M; Sancho JM; Gardella S; Coll R; García O; Gallardo D; Ribera JM
Med Clin (Barc); 2010 Jan; 134(2):72-5. PubMed ID: 19913261
[TBL] [Abstract][Full Text] [Related]
5. Incidence and Risk Factors of Infections Among Diffuse Large B-cell Lymphoma and Classical Hodgkin's Lymphoma Patients in a Tertiary Care Center in Saudi Arabia: A Retrospective Cohort Study.
Alelyani RH; Alghamdi AH; Almughamisi TA; Alshareef AM; Kadasa AN; Alrajhi AM; Alburayk AK; Barefah AS; Radhwi OO; Almohammadi AT; Bahashawan SM; AlAhwal HM
Cureus; 2023 Mar; 15(3):e35922. PubMed ID: 36911585
[TBL] [Abstract][Full Text] [Related]
6. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
[TBL] [Abstract][Full Text] [Related]
7. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).
Fridrik MA; Jaeger U; Petzer A; Willenbacher W; Keil F; Lang A; Andel J; Burgstaller S; Krieger O; Oberaigner W; Sihorsch K; Greil R
Eur J Cancer; 2016 May; 58():112-21. PubMed ID: 26990931
[TBL] [Abstract][Full Text] [Related]
8. [Interstitial pneumonia in patients with diffuse large B-cell lymphoma receiving RCHOP and RCDOP regimens].
Meng YN; Wang S; Shi Q; Xu PP; Cheng S; Wang L; Zhao WL
Zhonghua Xue Ye Xue Za Zhi; 2019 Dec; 40(12):1015-1020. PubMed ID: 32023732
[No Abstract] [Full Text] [Related]
9. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.
Ji D; Cao J; Hong X; Li J; Wang J; Chen F; Wang C; Zou S
Eur J Haematol; 2010 Sep; 85(3):243-50. PubMed ID: 20491883
[TBL] [Abstract][Full Text] [Related]
10. Analysis and evaluation of DRCOP scheme based on polyethylene glycol liposome doxorubicin in patients with diffuse large B-cell lymphoma.
Liu C; Zhang M
Am J Transl Res; 2021; 13(5):5362-5367. PubMed ID: 34150131
[TBL] [Abstract][Full Text] [Related]
11. Incidence of interstitial pneumonitis in non-Hodgkin's lymphoma patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab.
Zhou T; Shen Q; Peng H; Chao T; Zhang L; Huang L; Yang K; Thapa S; Yu S; Jiang Y
Ann Hematol; 2018 Jan; 97(1):141-147. PubMed ID: 29086009
[TBL] [Abstract][Full Text] [Related]
12. Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors.
Schmitt CJ; Dietrich S; Ho AD; Witzens-Harig M
Ann Hematol; 2012 Mar; 91(3):391-7. PubMed ID: 21850390
[TBL] [Abstract][Full Text] [Related]
13. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
[TBL] [Abstract][Full Text] [Related]
14. [Clinical Efficiency and Safety of the First-line CHOP Regimen Containing PLD Applied to Treat Aged Patients with Advanced DLBCL].
Li ZH; Xing MT; Zhang YP; Wang Y; Zhan XR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Jun; 24(3):744-8. PubMed ID: 27342502
[TBL] [Abstract][Full Text] [Related]
15. Prognostic values of various clinical factors and genetic subtypes for diffuse large B-cell lymphoma patients: a retrospective analysis of 227 cases.
Zhou D; Xie WZ; Hu KY; Huang WJ; Wei GQ; He JS; Shi JM; Luo Y; Li L; Zhu JJ; Zhang J; Lin MF; Ye XJ; Cai Z; Huang H
Asian Pac J Cancer Prev; 2013; 14(2):929-34. PubMed ID: 23621263
[TBL] [Abstract][Full Text] [Related]
16. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.
Knight C; Hind D; Brewer N; Abbott V
Health Technol Assess; 2004 Sep; 8(37):iii, ix-xi, 1-82. PubMed ID: 15361313
[TBL] [Abstract][Full Text] [Related]
17. Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma.
Shin HJ; Chung JS; Song MK; Kim SK; Choe S; Cho GJ
Cancer Chemother Pharmacol; 2012 May; 69(5):1165-72. PubMed ID: 22215473
[TBL] [Abstract][Full Text] [Related]
18. Limited stage diffuse large B-cell lymphoma: comparative effectiveness of treatment strategies in a large cohort of elderly patients.
Odejide OO; Cronin AM; Davidoff AJ; LaCasce AS; Abel GA
Leuk Lymphoma; 2015 Mar; 56(3):716-24. PubMed ID: 24913508
[TBL] [Abstract][Full Text] [Related]
19. Genetics and diffuse large B-Cell lymphoma.
Niroula R; Butera J
R I Med J (2013); 2015 Nov; 98(11):23-6. PubMed ID: 26517251
[TBL] [Abstract][Full Text] [Related]
20. Pegylated liposomal doxorubicin in the CHOP regimen for older patients with aggressive (stages III/IV) non-Hodgkin's lymphoma.
Tsavaris N; Kosmas C; Vadiaka M; Giannouli S; Siakantaris MP; Vassilakopoulos T; Pangalis GA
Anticancer Res; 2002; 22(3):1845-8. PubMed ID: 12168880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
